Regeneron halting higher doses in fasinumab trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said an IDMC recommended discontinuing two higher dose regimens of osteoarthritis (OA) and pain candidate fasinumab. Regeneron

Read the full 219 word article

User Sign In